胃内滞留性ドラッグデリバリーシステム市場の2030年までの予測： タイプ別、剤形別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、胃内滞留性ドラッグデリバリーシステムの世界市場は2023年に149億米ドルを占め、予測期間中にCAGR 12.1％で成長し、2030年には331億米ドルに達すると予測されています。

胃内滞留性ドラッグデリバリー」とは、医薬化合物を消化管内の標的部位に送達するために使用される方法、製剤、製造技術、保管システム、技術を指し、ドラッグデリバリーシステムの有効性と安全性を高めるために、医薬品の製造、投与経路、部位特異的標的、代謝、毒性に関する原則が適用されます。胃内滞留性ドラッグデリバリー法による粘膜保護の強化は、病態の予防と制御に利用できます。

アリゾナ大学が発表した論文によると、ピロリ菌感染は先進国よりも新興諸国の方が高いです。新興経済諸国では0.5％であるのに対し、発展途上国では人口の3～10％が新たに感染しています。

胃薬に対する需要の高まり

市場の成長は、バイオアベイラビリティの向上による投与量の削減や医薬品需要の増加とともに、胃内滞留性ドラッグデリバリーシステムの改善に向けた大手製薬会社の取り組みによって加速しています。さらに、消化性潰瘍や胃潰瘍を含む様々な種類の胃疾患の治療における胃保定薬物送達システムの有効性が確立されていることや、胃炎や胃がんの原因となるピロリ菌感染の有病率の増加が胃保定薬の使用を可能にし、市場拡大に大きく影響しています。

患者受容性の低下

このような新しい薬物送達技術は革新的であるため、患者に受け入れられにくい可能性があります。さらに、特に嚥下困難な患者や小さいサイズの剤形を好む患者にとっては、従来の経口剤形を好む場合もあります。さらに、一貫したコンプライアンスの確保も、患者が特定の投与指示に従うことに依存するため、困難です。そのため、胃内滞留性ドラッグデリバリーシステム（GRDDS）のサイズや特性を利便性が低いと感じる患者もおり、市場は大きく後退する可能性があります。

技術の進歩

胃内滞留性ドラッグデリバリー技術の使用は、バイオアベイラビリティを高めながら、様々な医薬品の投与量をコントロールする効果的な技術であることが証明されています。さらに、不規則な胃の空っぽのタイミングや短い胃残留時間のような物理的課題を超える技術革新が、近年、制御された経口薬投与システムの改善につながりました。さらに、once-GRDDSは上部消化管での滞留時間を延長することで、治療効果と経口バイオアベイラビリティを向上させることができます。したがって、これらの進歩が市場規模を押し上げる原動力となっています。

製剤化に伴うリスク

薬物を制御された速度で放出しながら、一貫して消化管粘膜に付着したり胃の中で浮遊したりする薬理学的製剤を作るには、克服すべき課題があります。さらに、粘着性、浮力、放出制御のこのバランスを達成するには、正確な製剤法と綿密な調査が必要です。さらに、胃腸環境における薬物の安定性を確保する必要があるため、難易度はさらに高まる。したがって、こうした困難はしばしば開発期間の長期化や価格の上昇につながり、市場の成長に影響を及ぼします。

COVID-19の影響

胃内滞留性ドラッグデリバリーシステム（GRDDS）市場は、COVID-19の流行によってマイナスの影響を受けています。GRDDSベースの医薬品開発のための臨床試験や研究は、ヘルスケア・システムがウイルス対策に集中する間に遅れました。さらに、医療施設へのアクセスが制限され、臨床試験への患者の募集や革新的なドラッグデリバリー方法の導入に影響が出ました。さらに、経済的な制約とサプライチェーンの中断が、GRDDS商品の製造と流通を妨げました。そのため、パンデミックによるヘルスケアシステムへの財政負担の増大の結果、新規ドラッグデリバリー法の予算が影響を受け、市場の成長が徐々に阻害されるようになっています。

浮遊式ドラッグデリバリーシステム（FDDS）分野が予測期間中最大になる見込み

浮遊型ドラッグデリバリーシステム分野が最大のシェアを占めると推定されます。これらは、胃の中で長時間浮いたままの薬剤製剤です。さらに、これらの方法では胃液に浮きながら薬剤を徐々に放出することができるため、薬剤の吸収が向上し、治療効果が延長します。フローティング・ドラッグデリバリー・システム（FDDS）は、副作用を軽減し、投与回数を減らし、薬物吸収を高めることができます。さらに、吸収ウィンドウが小さい薬剤には特に有効で、さまざまな胃腸疾患の治療に用いられています。したがって、薬物送達を改善する最先端の方法であるFDDSは、患者のコンプライアンスを高め、胃腸滞留性医薬品の治療効果を保証し、それによって市場の拡大を増大させる。

マイクロスフェアセグメントは予測期間中最も高いCAGRが見込まれる

微小球セグメントは、胃腸管での医薬品の吸収を改善するために、医薬品の製剤に小さな球状の粒子を使用するため、予測期間中に最も高いCAGRが予想されます。さらに、これらの微小球は放出制御のために薬剤を含むことができ、一般的に生体適合性物質で作られています。これらは、より長い薬剤投与、投与回数の減少、副作用の減少など、消費後の利点を提供します。ミクロスフェアを用いたGRDDSは、様々な胃腸疾患の治療に使用され、患者のコンプライアンスと治療効果を高めています。したがって、このセクションは、消化器系の薬物吸収と治療効果を高める独自の薬理学的戦略を示しており、市場を大きく牽引しています。

最大のシェアを占める地域

アジア太平洋地域は、薬物吸収と患者のコンプライアンスに優れているため、予測期間中に最大の市場シェアを占めました。さらに、アジア太平洋地域は医療研究とインフラ整備に資金を費やしており、これが技術革新と市場成長を促しています。GRDDSの採用は、規制の変更や慢性疾患の増加によってさらに加速しています。このため、GRDDS業界の薬局、研究者、医療従事者は、この地域で多くのチャンスを手にしています。

CAGRが最も高い地域：

欧州はGRDDS技術の進歩に大きな役割を果たし、イノベーションと質の高いヘルスケアの両方に重点を置いているため、予測期間中に最も高いCAGRを示すと予想されます。また、同地域では高齢化が進み、消化器疾患の有病率が高いため、より優れたドラッグデリバリー方法が求められています。さらに、治療成績、患者のコンプライアンス、生活の質を向上させるため、欧州のヘルスケアシステムはGRDDSの開発と展開を奨励しています。したがって、厳格な規制基準により製品の安全性が確保され、活気ある市場となっています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の胃滞留型ドラッグデリバリーシステム市場：タイプ別

• 拡張可能なドラッグデリバリーシステム
• 生体接着性ドラッグデリバリーシステム
• 浮遊ドラッグデリバリーシステム（FDDS）
• 高密度システム
• その他のタイプ

第6章 世界の胃滞留型ドラッグデリバリーシステム市場：剤形別

• ミクロスフェア
• タブレット
• カプセル
• その他の剤形

第7章 世界の胃滞留型ドラッグデリバリーシステム市場：流通チャネル別

• オンライン薬局
• 病院薬局
• 小売薬局
• その他の流通チャネル

第8章 世界の胃滞留型ドラッグデリバリーシステム市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Ranbaxy
• GlaxoSmithKline
• Competition Deep Dive
• Depomed
• Pharmacia
• Alcon, Inc.
• Lupin
• Galanix
• Sun Pharma
• F. Hoffmann La Roche

List of Tables

• Table 1 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Expandable Drug Delivery System (2021-2030) ($MN)
• Table 4 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Bioadhesive Drug Delivery System (2021-2030) ($MN)
• Table 5 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Floating Drug Delivery System (FDDS) (2021-2030) ($MN)
• Table 6 Global Gastro-retentive Drug Delivery Systems Market Outlook, By High Density System (2021-2030) ($MN)
• Table 7 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Other Types (2021-2030) ($MN)
• Table 8 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 9 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Microspheres (2021-2030) ($MN)
• Table 10 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Tablets (2021-2030) ($MN)
• Table 11 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Capsule (2021-2030) ($MN)
• Table 12 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 13 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 14 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 15 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 16 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 17 Global Gastro-retentive Drug Delivery Systems Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 18 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Type (2021-2030) ($MN)
• Table 20 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Expandable Drug Delivery System (2021-2030) ($MN)
• Table 21 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Bioadhesive Drug Delivery System (2021-2030) ($MN)
• Table 22 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Floating Drug Delivery System (FDDS) (2021-2030) ($MN)
• Table 23 North America Gastro-retentive Drug Delivery Systems Market Outlook, By High Density System (2021-2030) ($MN)
• Table 24 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Other Types (2021-2030) ($MN)
• Table 25 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 26 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Microspheres (2021-2030) ($MN)
• Table 27 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Tablets (2021-2030) ($MN)
• Table 28 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Capsule (2021-2030) ($MN)
• Table 29 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 30 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 31 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 32 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 33 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 34 North America Gastro-retentive Drug Delivery Systems Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 35 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Type (2021-2030) ($MN)
• Table 37 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Expandable Drug Delivery System (2021-2030) ($MN)
• Table 38 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Bioadhesive Drug Delivery System (2021-2030) ($MN)
• Table 39 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Floating Drug Delivery System (FDDS) (2021-2030) ($MN)
• Table 40 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By High Density System (2021-2030) ($MN)
• Table 41 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Other Types (2021-2030) ($MN)
• Table 42 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 43 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Microspheres (2021-2030) ($MN)
• Table 44 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Tablets (2021-2030) ($MN)
• Table 45 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Capsule (2021-2030) ($MN)
• Table 46 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 47 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 48 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 49 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 50 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 51 Europe Gastro-retentive Drug Delivery Systems Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 52 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Type (2021-2030) ($MN)
• Table 54 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Expandable Drug Delivery System (2021-2030) ($MN)
• Table 55 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Bioadhesive Drug Delivery System (2021-2030) ($MN)
• Table 56 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Floating Drug Delivery System (FDDS) (2021-2030) ($MN)
• Table 57 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By High Density System (2021-2030) ($MN)
• Table 58 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Other Types (2021-2030) ($MN)
• Table 59 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 60 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Microspheres (2021-2030) ($MN)
• Table 61 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Tablets (2021-2030) ($MN)
• Table 62 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Capsule (2021-2030) ($MN)
• Table 63 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 64 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 65 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 66 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 67 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 68 Asia Pacific Gastro-retentive Drug Delivery Systems Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 69 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Type (2021-2030) ($MN)
• Table 71 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Expandable Drug Delivery System (2021-2030) ($MN)
• Table 72 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Bioadhesive Drug Delivery System (2021-2030) ($MN)
• Table 73 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Floating Drug Delivery System (FDDS) (2021-2030) ($MN)
• Table 74 South America Gastro-retentive Drug Delivery Systems Market Outlook, By High Density System (2021-2030) ($MN)
• Table 75 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Other Types (2021-2030) ($MN)
• Table 76 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 77 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Microspheres (2021-2030) ($MN)
• Table 78 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Tablets (2021-2030) ($MN)
• Table 79 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Capsule (2021-2030) ($MN)
• Table 80 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 81 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 82 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 83 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 84 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 85 South America Gastro-retentive Drug Delivery Systems Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 86 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Type (2021-2030) ($MN)
• Table 88 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Expandable Drug Delivery System (2021-2030) ($MN)
• Table 89 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Bioadhesive Drug Delivery System (2021-2030) ($MN)
• Table 90 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Floating Drug Delivery System (FDDS) (2021-2030) ($MN)
• Table 91 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By High Density System (2021-2030) ($MN)
• Table 92 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Other Types (2021-2030) ($MN)
• Table 93 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 94 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Microspheres (2021-2030) ($MN)
• Table 95 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Tablets (2021-2030) ($MN)
• Table 96 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Capsule (2021-2030) ($MN)
• Table 97 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 98 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 99 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 100 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 101 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 102 Middle East & Africa Gastro-retentive Drug Delivery Systems Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

According to Stratistics MRC, the Global Gastro-retentive Drug Delivery Systems Market is accounted for $14.9 billion in 2023 and is expected to reach $33.1 billion by 2030 growing at a CAGR of 12.1% during the forecast period. The term "gastro-retentive drug delivery" refers to methods, formulations, production techniques, storage systems, and technologies used to deliver pharmaceutical compounds to the target location in the gastro-intestinal tract, to enhance the effectiveness and safety of a drug delivery system, principles relating to drug manufacturing, route of administration, site-specific targeting, metabolism, and toxicity are applied. The enhancement of mucosal protection by the gastro-retentive drug delivery method can be used to prevent and control the condition.

According to the article published by the University of Arizona, H.pylori infection is higher in developing countries than the developed countries. The incidence of new infections in developing countries is 3 to 10% of the population compared to 0.5% in developed economies.

Market Dynamics:

Driver:

Rising demand for gastro-retentive drugs

The market's growth has been accelerated by large pharmaceutical companies' efforts to improve gastro-retentive drug delivery systems, together with dose reductions due to improved bioavailability and an increase in the demand for drugs. Additionally, the market is greatly influenced by the well-established effectiveness of gastro-retentive drug delivery systems in treating various kinds of stomach disorders, including peptic ulcer and gastric ulcer, as well as an increase in the prevalence of H.pylori infection, which can lead to gastritis and gastric cancer which enabled the use of gastro-retentive drugs resulting in market expansion.

Restraint:

Decrease in Patient acceptance

The innovative nature of these new medicine delivery techniques may make them difficult for patients to accept. Additionally, patients may prefer traditional oral dosage forms especially for individuals who have difficulty swallowing or who prefer smaller-sized dosage forms. Moreover, ensuring consistent compliance is also challenging, as it relies on patients following specific administration instructions. Thus, some patients may find the size or characteristics of Gastro-retentive Drug Delivery Systems (GRDDS) less convenient by which the market gets significantly retrain.

Opportunity:

Technological advancements

The use of gastro-retentive drug delivery technology has proven to be an effective technique to control the dosage of a variety of pharmaceuticals while increasing bioavailability. Moreover, technology innovations that go beyond physical challenges like erratic stomach emptying timings and brief gastric residency times have led to improvements in controlled oral medicine administration systems in recent years. Additionally, once-GRDDS can improve therapeutic effectiveness and oral bioavailability by prolonging their duration in the upper GI tract. Hence, these advancements drive the market size.

Threat:

Risks associated while formulating

There are challenging obstacles to overcome when creating pharmacological formulations that can consistently stick to the gastrointestinal mucosa or float in the stomach while releasing the drug at a controlled rate. Moreover, it takes exact formulation methods and in-depth research to achieve this balance of adhesion, buoyancy, and controlled release. Additionally, the difficulty is increased further by the need to ensure the drug's stability in the gastrointestinal environment. Therefore, these difficulties frequently lead to longer development times and higher prices, which have an effect on market growth.

COVID-19 Impact

The market for gastro-retentive drug delivery systems (GRDDS) has been negatively impacted by the COVID-19 epidemic. Clinical trials and research for the development of GRDDS-based drugs were delayed while healthcare systems concentrated on fighting the virus. Additionally, access to medical facilities became restricted, which had an impact on the recruitment of patients for clinical trials and the uptake of innovative drug delivery methods. Moreover, economical limitations and supply chain interruptions have hampered the manufacture and distribution of GRDDS goods. Therefore, budgets for novel drug delivery methods were impacted as a result of the pandemic's increasing financial load on healthcare systems which gradually hampered the market growth.

The floating drug delivery system (FDDS) segment is expected to be the largest during the forecast period

The floating drug delivery system segment is estimated to hold the largest share. These are drug formulations that remain buoyant in the stomach for an extended period. Additionally, these methods allow medications to release gradually while floating on the gastric fluid, improving drug absorption and extending therapeutic benefits. Floating drug delivery system (FDDS) can reduce side effects, decrease dosage frequency, and increase drug absorption. Furthermore, they are particularly helpful for medications with small absorption windows and are used in the treatment of a variety of gastrointestinal ailments. Therefore, a cutting-edge method for improving medication delivery, FDDS ensures higher patient compliance and therapeutic effectiveness in gastro-retentive medicines thereby increasing the market expansion.

The microspheres segment is expected to have the highest CAGR during the forecast period

The microspheres segment is anticipated to have highest CAGR during the forecast period due to the use of small, spherical particles in medicine formulations to improve absorption of the medicament in the gastrointestinal tract. Additionally, these microspheres can contain medications for controlled release and are typically made of biocompatible substances. They provide advantages after consumption, including longer drug administration, decreased dosage frequency, and reduced side effects. GRDDS with microspheres is used to treat a variety of gastrointestinal illnesses, enhancing patient compliance and therapeutic results. Hence, this section shows an original pharmacological strategy for enhancing gastrointestinal system drug absorption and therapeutic efficacy by significantly driving the market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to due to their better drug absorption and patient compliance. Additionally, the Asia-Pacific region is spending money on medical research and infrastructure, which encourages innovation and market growth. Adoption of GRDDS is further fuelled by regulatory changes and the rise in chronic diseases. Therefore, pharmacies, researchers, and healthcare practitioners in the GRDDS industry have a lot of opportunities in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to a major role in the advancement of GRDDS technology, placing a strong emphasis on both innovation and high-quality healthcare. Additionally, there is a need for better drug delivery methods due to the aging population in the area and the high prevalence of gastrointestinal illnesses. Moreover, in order to improve treatment outcomes, patient compliance, and quality of life, European healthcare systems encourage the development and deployment of GRDDS. Hence, stringent regulatory standards ensure product safety, making it a thriving market.

Key players in the market:

Some of the key players in the Gastro-retentive Drug Delivery Systems Market include: Ranbaxy, GlaxoSmithKline, Competition Deep Dive, Depomed, Pharmacia, Alcon, Inc., Lupin, Galanix, Sun Pharma and F. Hoffmann La Roche.

Key Developments:

In October 2023, Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for deuruxolitinib, an investigational oral selective inhibitor of Janus kinases, for the treatment of adults with moderate to severe alopecia areata.

In March 2023, Sun Pharmaceutical Industries Limited announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia area.

Types Covered:

• Expandable Drug Delivery System
• Bioadhesive Drug Delivery System
• Floating Drug Delivery System
• High Density System
• Other Types

Dosage Forms Covered:

• Microspheres
• Tablets
• Capsule
• Other Dosage Forms

Distribution Channels Covered:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gastro-retentive Drug Delivery Systems Market, By Type

• 5.1 Introduction
• 5.2 Expandable Drug Delivery System
• 5.3 Bioadhesive Drug Delivery System
• 5.4 Floating Drug Delivery System (FDDS)
• 5.5 High Density System
• 5.6 Other Types

6 Global Gastro-retentive Drug Delivery Systems Market, By Dosage Form

• 6.1 Introduction
• 6.2 Microspheres
• 6.3 Tablets
• 6.4 Capsule
• 6.5 Other Dosage Forms

7 Global Gastro-retentive Drug Delivery Systems Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Online Pharmacies
• 7.3 Hospital Pharmacies
• 7.4 Retail Pharmacies
• 7.5 Other Distribution Channels

8 Global Gastro-retentive Drug Delivery Systems Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Ranbaxy
• 10.2 GlaxoSmithKline
• 10.3 Competition Deep Dive
• 10.4 Depomed
• 10.5 Pharmacia
• 10.6 Alcon, Inc.
• 10.7 Lupin
• 10.8 Galanix
• 10.9 Sun Pharma
• 10.10 F. Hoffmann La Roche